


copy of papers  
originally filed

Sheet 1 of 5



**COPY OF PAPER  
ORIGINALLY FILED**

Sheet 2 of 5

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)		Docket Number <b>72535</b>		Application Number <b>10/008,955</b>			
		Applicant <b>Hans KLINGEMANN</b>		Group Art Unit  <b>U. S. PATENT DOCUMENTS</b>			
		Filing Date <b>December 7, 2001</b>					
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.	
<b>RECEIVED</b> MAR - 4 2002 <b>TECH CENTER 1600/2900</b>							
<b>FOREIGN PATENT DOCUMENTS</b>							
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	<b>Translation</b> <input checked="" type="checkbox"/> Yes <input type="checkbox"/> No	
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)							
	Robertson, M. J., et al., "Biology and Clinical Relevance of Human Natural Killer Cells", <u>Blood</u> , Vol. 76, No. 12, (December 15), 1990: pp. 2421-2438						
	Ellis, T. M., et al., "Functional Heterogeneity of Leu 19 <sup>bright</sup> and Leu 19 <sup>dim</sup> Lymphokine-Activated Killer Cells", <u>The Journal of Immunology</u> , Vol. 142, April 15, 1989, No. 8, pp. 2949-2954						
	Ades, E. W., "Lymphokine-Activated Killer Cell Lysis of Human Neuroblastoma Cells: A Model for Purging Tumor Cells from Bone Marrow", <u>Clinical Immunology and Immunopathology</u> , 46, pp. 150-156 (1988)						
	Tsuchiya, J. et al., "Characterization of a Novel Human Natural Killer-Cell Line (ND-YS) Established from Natural Killer Cell Lymphoma/Leukemia Associated with Epstein-Barr Virus Infection", <u>Blood</u> , Vol. 92, No. 4, (August 15), 1988: pp. 1374-1383						
	Ingo, G. H., et al., "Use of a SCID Mouse/Human Lymphoma Model to Evaluate Cytokine-induced Killer Cells with Potent Antitumor Cell Activity", <u>J. Exp. Med.</u> , Vol. 174, July 1991, pp. 139-149						
<b>EXAMINER</b> 	<b>DATE CONSIDERED</b> <b>5/2/02</b>						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant							



COPY OF PAPERS  
ORIGINALLY ISSUED

Sheet 3 of 5

<b>INFORMATION DISCLOSURE CITATION IN AN APPLICATION</b>  (Use several sheets if necessary)		Docket Number <b>72535</b>		Application Number <b>10/008,955</b>		
		Applicant <b>Hans KLINGEMANN</b>				
		Filing Date <b>December 7, 2001</b>		Group Art Unit <b>Group Art Unit</b>		
<b>U. S. PATENT DOCUMENTS</b>						
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
<b>RECEIVED</b> <b>MAR - 4 2002</b> <b>TECH CENTER 1600/2000</b>						
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	Translation
						Yes
<b>OTHER DOCUMENTS</b> (Including Author, Title, Date, Pertinent Pages, Etc.)						
<b>(M)</b>	Hercend, T., et al., "Phenotypic and functional heterogeneity of human cloned natural killer cell lines", <u>Nature</u> , Vol. 301, January 13, 1983, pp. 158-160					
<b>(✓)</b>	Alderson, M. R., "Interleukin 7 Enhances Cytolytic T Lymphocyte Generation and Induces Lymphokine-activated Killer Cells from Human Peripheral Blood", <u>J. Exp. Med.</u> , Vol. 172, August 1990, pp. 577-587					
<b>(✓)</b>	Robertson, M. J., et al., "Response of Human Natural Killer (NK) Cells to NK Cell Stimulatory Factor (NKSF): Cytolytic Activity and Proliferation of NK Cells are Differentially Regulated by NKSF", <u>J. Exp. Med.</u> , March 1992, pp. 779-788					
<b>(✓)</b>	Phillips, J. H., et al., "Dissection of the Lymphokine-Activated Killer Phenomenon", <u>J. Exp. Med.</u> , Vol. 164, September 1986, pp. 814-825					
<b>(✓)</b>	Rosenberg, S. A., et al., "Special Report - Observation on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer", <u>The New England Journal of Medicine</u> , Vol. 313, No. 23, Dec. 5, 1985, pp. 1485-1492					
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		
5/24/02						
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant						



copy of papers  
originally filed

Sheet 4 of 5

FER 27 2002